Ostsukaa Announces Phase 3 Topline Results Of AVP-786 In Treatment Of Agitation Associated With Dementia Due To Alzheimer's Disease
12/02/2024 23:09
Feb 13 (Reuters) - Otsuka Holdings Co Ltd 4578.T :
* OTSUKA ANNOUNCES PHASE 3 TOPLINE RESULTS OF AVP-786 IN
TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO
ALZHEIMER'S DISEASE
* OTSUKA HOLDINGS CO LTD: IN THE FOURTH QUARTER OF THIS
FISCAL
YEAR, THE COMPANY EXPECTS TO RECORD AN IMPAIRMENT LOSS OF
APPROXIMATELY ¥115 BILLION IN AVP-786
Source text for Eikon: ID:nTSnl82299
Further company coverage: 4578.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug